MAM, on the other hand, plays an important role in innate immune cell response to ER stress and serves as a site of NLRP3 inflammasome activation under stress conditions, implying that MAM could serve as a novel potential therapeutic target for inflammatory‐related metabolic diseases. The gene discussed is SGCG; the disease is metabolic disease.